Board of Directors
|
Mr. Ross Haghighat - Chairman of the Board Mr. Ross Haghighat is a serial entrepreneur with nearly 25 years of experience in founding and transforming companies in the high tech fields of telecommunications, sensors and diagnostics, biotechnology, and specialty materials. He is the founding CEO of Triton Systems, Inc., a leading product venturing company headquartered in Chelmsford Massachusetts, a suburb of Boston and with offices in Boston, Washington DC, and Fargo, North Dakota. Mr. Haghighat serves on the Board of a number of for profit firms: Triton Systems, Aduro BioTech, SI2 Technologies, FRX Polymers Sensera . |
|
Mr. Jerry Korten - Director Jerry Korten was CEO of Versamed, Inc. an Israeli startup he helped establish as a US company that was sold to GE Healthcare. Currently Jerry, as General Manager of Strategic Markets, is working with GE Healthcare to identify new opportunities to advance technology in the field of cardiopulmonary therapy, monitoring and diagnosis. Jerry also serves as a mentor to the New York City Investment Fund's BioAccelerate Program to catalyze the creation of a life sciences industry sector in the city by increasing the number of commercial spin-offs from New York’s universities and research institutions. Jerry has served on the boards of diagnostic and therapeutic device companies including Versamed, Inc., Bunnel Inc. and Vitaltrends Technology, Inc. and brings operational expertise in running medical device companies including engineering management as well as management experience in sales and marketing. |
|
Dr. David Dantzker - Director Dr David R. Dantzker, M.D., is general partner at Wheatley Partners, LP, and former Chairman of Pulmonary Disease for the American Board of Internal Medicine, brings more than 10 years of medical technology portfolio management and corporate board experience to iSonea.As a general partner at Wheatley Partners, Dr. Dantzker manages the medical technology portfolio of investments for the US-based $250 million venture capital fund. Dr. Dantzker also brings extensive pulmonary medicine experience to iSonea’s BOD. Before joining Wheatley Partners, Dr. Dantzker held several executive positions at some of the country’s most prestigious medical institutions, including president of North Shore-Long Island Jewish Health System; vice chairman of the Department of Internal Medicine and director of the Pulmonary and Critical Care Medicine division at the University of Texas Health Science Center; and chairman of the American Board of Internal Medicine as well as its subspecialty board of Pulmonary Disease. He has authored 68 peer reviewed articles and edited five books.
Dr. Washer has 15 years of senior executive and Board experience at medical device, drug development and agrifood companies. He was a venture partner with Inventages, a Nestlé fund and is currently Investment Manager with IB Managers, which manages Australian life-science funds. Dr. Washer was previously the CEO of Calzada Ltd (ASX: CZD); the founding CEO of Phylogica Ltd (ASX: PYC); CEO of Celentis; and managed the commercialization of intellectual property from AgResearch in New Zealand. He has held a number of Board positions, including Chairman of Resonance Health Ltd (ASX: RHT) and Hatchtech Pty Ltd; and Director of iCeutica Pty Ltd and AusBiotech Ltd. He was also a Senator with Murdoch University and is currently a Director of Healthlinx Ltd (ASX: HTX) and Immuron Ltd (ASX: IMC).
Dr. MacDonald brings extensive local and international biomedical experience in general management, technology commercialisation, capital raising, and business development, including licensing, mergers and acquisitions. He was formerly Managing Director and CEO of Living Cell Technologies Ltd (ASX: LCT; OTCQX: LVCLY), a development stage biotechnology company focused on therapeutics for type-1 diabetes, Parkinson’s disease, and stroke. Dr. Macdonald is currently a Member of the Investment Committee of Uniseed Management Pty Ltd, a venture fund established to commercialise research outcomes from the Universities of Queensland, Melbourne and New South Wales, and serves as a Director for pharmaceutical development companies Telesso Technologies Ltd (ASX: TEO) and Hatchtech Pty Ltd. Previously he held VP positions at, Sinclair Pharmaceuticals Ltd, Stiefel Laboratories, Inc., Connetics Corporation and for F.H. Faulding & Co, Ltd, Australia’s largest and oldest pharmaceutical company.
Mr. Donal O’Dwyer brings extensive worldwide sales, marketing, product development and manufacturing operations experience in the healthcare products and medical device industries. He was formerly Worldwide President of Cordis Cardiology, a Johnson & Johnson Company, during which time he re-established their position as a leader in international cardiology with the development and launch of the revolutionary Cypher coronary stent. He oversaw the growth of that business from USD500M per annum to over USD2B per annum. Mr. O’Dwyer is currently Deputy Chairman of the Board at Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY), the world’s leading developer of biological products for regenerative medicine. He is also a member of the Board at Cochlear, the leading global hearing solution company. Previously, he was President of the Cardiovascular Group, Europe, for Baxter Healthcare. He was chairman of the Board of AtCor Medical and has served as Director on the Boards of Angioblast Systems and Sunshine Heart.
|
